The UK’s Prostrakan has signed a deal with Scandinavian firm Orexo to establish a jointly-owned salesforce that will cover the Nordic markets of Sweden, Norway, Finland, Denmark and Iceland.
The new entity will sell both currently marketed and future products belonging to both firms, including Tostrex (testosterone replacement therapy), the rectal ointment Rectogesic (glyceryl trinitrate), and the antipsychotic/antiemetic agent droperidol. Expected onto the market shortly are Orexo's cancer pain agent Rapinyl (sublingual fentanyl), for which ProStrakan holds the European distribution rights, and ProStrakan's product Sancuso (granisetron) for the prevention of chemotherapy-induced nausea and vomiting. Both products are currently undergoing the European regulatory process.
ProStrakan's existing Swedish affiliate, ProStrakan AB, will be used as the holding firm and will trade under this name and be based in Malmo, Sweden. Orexo is investing £1.3 million to acquire 50% of it.
Dr Wilson Totten, Chief Executive of ProStrakan, said: "The Nordic countries are very important to ProStrakan and eaming up with Orexo will considerably boost the ability of both companies to enhance our performance in this market and increase sales.”